Logo

Vox Markets

Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.

Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.

0 views
3 years ago
Author: Vox Markets

Money
Investing
AIM
Stock Market
Equities
Poolbeg
Stocks to Follow
AI
Markets
POLB
Hot Stocks
Powered bySeeen logo